Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sutro Biopharma Inc (NQ: STRO )

4.745 +0.735 (+18.33%)
Streaming Delayed Price Updated: 11:24 AM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,514,886
Open 4.610
Bid (Size) 4.740 (1)
Ask (Size) 4.750 (5)
Prev. Close 4.010
Today's Range 4.370 - 5.090
52wk Range 2.005 - 5.880
Shares Outstanding 60,416,916
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
STRO Stock Earnings: Sutro Biopharma Misses EPS, Beats Revenue for Q1 2024
STRO stock results show that Sutro Biopharma missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Expert Outlook: Sutro Biopharma Through The Eyes Of 10 Analysts
Via Benzinga

Performance

YTD
+3.83%
+3.83%
1 Month
+30.72%
+30.72%
3 Month
+0.74%
+0.74%
6 Month
+71.30%
+71.30%
1 Year
-10.64%
-10.64%

More News

Read More
What's Going On With Sutro Biopharma (STRO) Stock?
Via Benzinga
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Navigating 4 Analyst Ratings For Sutro Biopharma
Via Benzinga
Expert Ratings for Sutro Biopharma
Via Benzinga
Where Sutro Biopharma Stands With Analysts
Via Benzinga
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
STRO Stock Earnings: Sutro Biopharma Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
5 Analysts Have This to Say About Sutro Biopharma
Via Benzinga
Where Sutro Biopharma Stands With Analysts
Via Benzinga
6 Analysts Have This to Say About Sutro Biopharma
Via Benzinga
Sutro Biopharma Earnings Perspective: Return On Capital Employed
Via Benzinga
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
From Vaxcyte, Inc.
Via GlobeNewswire
Sutro Biopharma's Lead Ovarian Cancer Candidate Is A Game Changer, Analyst Sees Huge Upside
Via Benzinga
Why Monro Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Where Sutro Biopharma Stands With Analysts
Via Benzinga
Sutro Biopharma Posts Updated Data From Ovarian Cancer Candidate
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
Via Benzinga
Super Micro Computer, Rayonier Advanced Materials And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.